<unk>  is a tumor necrosis factor inhibitor that is FDA approved for the treatment of moderately to severely active rheumatoid arthritis (RA), active psoriatic arthritis (PsA), active ankylosing spondylitis (AS); and moderate to severe Ulcerative colitis (UC) with an inadequate response or intolerant to prior treatment or requiring continuous steroid therapy. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include upper respiratory tract infection, nasopharyngitis and injection site reactions.
Golimumab
Belimumab
Sarilumab
Belatacept
Tofacitinib
Adalimumab
Avelumab
Nebacumab